Advanced

Primary prophylaxis in haemophilia care : Guideline update 2016

Fischer, Kathelijn and Ljung, Rolf LU (2016) In Blood Cells, Molecules, and Diseases
Abstract

This paper reviews the current status on recommendations or guidelines for primary prophylaxis based on recent published papers from organizations or group of experts as well as some original key papers. A rather uniform view exists that prophylaxis should be initiated at an early age before or after no more than a single joint bleed and, if possible, preferably be continued for life. The dose and dose frequency of prophylaxis is dependent on the goal of treatment, bleeding phenotype, compliance, venous access and economic resources in the health care system and should be tailored individually based on clinical outcome and pharmacokinetics. For children, the effectiveness of prophylaxis is more dependent on maintaining minimum trough... (More)

This paper reviews the current status on recommendations or guidelines for primary prophylaxis based on recent published papers from organizations or group of experts as well as some original key papers. A rather uniform view exists that prophylaxis should be initiated at an early age before or after no more than a single joint bleed and, if possible, preferably be continued for life. The dose and dose frequency of prophylaxis is dependent on the goal of treatment, bleeding phenotype, compliance, venous access and economic resources in the health care system and should be tailored individually based on clinical outcome and pharmacokinetics. For children, the effectiveness of prophylaxis is more dependent on maintaining minimum trough levels than in adults. Novel extended half-life products are being introduced, which should not affect the decision on when to start prophylaxis nor the initial dose, but which may be helpful for patients with difficult venous access and which may enable higher trough levels of factor VIII.

(Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
in press
subject
in
Blood Cells, Molecules, and Diseases
publisher
Elsevier
external identifiers
  • scopus:85016840096
ISSN
1079-9796
DOI
10.1016/j.bcmd.2017.03.009
language
English
LU publication?
yes
id
761fbedc-ddce-4927-99e7-5bdfa1913a6f
date added to LUP
2018-10-12 09:51:55
date last changed
2019-04-23 04:40:25
@article{761fbedc-ddce-4927-99e7-5bdfa1913a6f,
  abstract     = {<p>This paper reviews the current status on recommendations or guidelines for primary prophylaxis based on recent published papers from organizations or group of experts as well as some original key papers. A rather uniform view exists that prophylaxis should be initiated at an early age before or after no more than a single joint bleed and, if possible, preferably be continued for life. The dose and dose frequency of prophylaxis is dependent on the goal of treatment, bleeding phenotype, compliance, venous access and economic resources in the health care system and should be tailored individually based on clinical outcome and pharmacokinetics. For children, the effectiveness of prophylaxis is more dependent on maintaining minimum trough levels than in adults. Novel extended half-life products are being introduced, which should not affect the decision on when to start prophylaxis nor the initial dose, but which may be helpful for patients with difficult venous access and which may enable higher trough levels of factor VIII.</p>},
  author       = {Fischer, Kathelijn and Ljung, Rolf},
  issn         = {1079-9796},
  language     = {eng},
  month        = {11},
  publisher    = {Elsevier},
  series       = {Blood Cells, Molecules, and Diseases},
  title        = {Primary prophylaxis in haemophilia care : Guideline update 2016},
  url          = {http://dx.doi.org/10.1016/j.bcmd.2017.03.009},
  year         = {2016},
}